Ilsung Pharmaceuticals Overview
- Founded
-
1961
- Status
-
Public
- Employees
-
228
- Stock Symbol
-
003120
- Share Price
-
$70.10
- (As of Friday Closing)
Ilsung Pharmaceuticals General Information
Description
Ilsung Pharmaceuticals Co Ltd is a South Korea based company engages in the development, manufacture, and sale of pharmaceutical products. It offers antibiotics; diagnostics, including contrast media; and products for cardiovascular, GI tract, metabolism disorders, ophthalmological disorders, and inhalation anesthetics.
Contact Information
Website
www.ilsung-ph.co.kr
Formerly Known As
Ilsung Corporation
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
KRX
Primary Office
- 84-gil 9 Wonhyo-ro Yongsan-ku
- Seoul
- South Korea
+82 00-0000-0000
Ilsung Pharmaceuticals Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $70.10 | $69.89 | $55.86 - $104.89 | $104M | 1.48M | 4.41K | $57.34 |
Ilsung Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | (145,687) | 41,417 | 75,202 | 63,955 |
| Revenue | 45,418 | 36,746 | 34,387 | 41,517 |
| EBITDA | 43,171 | 1,102 | 5,755 | 9,940 |
| Net Income | 85,825 | (1,194) | 2,727 | 5,762 |
| Total Assets | 345,702 | 312,081 | 340,286 | 319,002 |
| Total Debt | 238 | 152 | 405 | 109 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ilsung Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ilsung Pharmaceuticals Patents
Ilsung Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-1931330-A1 | Composition comprising tanshinone compounds isolated from the extract of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction and the use thereof | Inactive | 06-Oct-2005 | 0000000000 | |
| US-20090312413-A1 | Composition comprising tanshinone compounds isolated from the extract of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction and the use thereof | Inactive | 06-Oct-2005 | 0000000000 |
Ilsung Pharmaceuticals Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Seok geun Yoon | Chief Executive Officer |
Ilsung Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
